Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/156—Polymorphic or mutational markers
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/10—Musculoskeletal or connective tissue disorders
  • G01N2800/108—Osteoporosis
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present application generally relates to methods for diagnosing bone loss. More specifically, the present application relates to identifying humoral markers for bone loss on the basis of bacterial or mammalian molecular chaperones.
• Osteoporosis is a systemic disorder characterized by decreased bone mass and microarchitectural deterioration of bone tissue leading to bone fragility and increased susceptibility to fractures of hip, spine, and wrist. Osteopenia has been defined as the appearance of decreased bone mineral content on radiography, but the term more appropriately refers to a phase in the continuum from decreased bone mass to fractures and infirmity. By the time the diagnosis of osteopenia is made radiographically, significant and irreversible bone loss has already occurred. The most common cause of osteopenia is osteoporosis; other causes include osteomalacia and the bone disease of hyp erp ar athy r oidis .
• Osteoporosis develops less often in men than women because bone loss starts later and progresses more slowly in men, and there is no period of rapid hormonal change and accompanying rapid bone loss. Differences in bone geometry and remodeling also contribute to the lower rate of fractures in men. However, in the past few years, the problem of osteoporosis in men has become recognized as an important public health issue, particularly in hght of estimates that the number of men older than 70 will double between 1993 and 2050 according to the US National Osteoporosis Foundation.
• a method of detecting osteoporosis in a mammal includes the steps of a) obtaining a sample of a bone related tissue or cells; and b) measuring the concentration of at least a marker which is one of bacteria, bacteria produced factors, or heat shock proteins (HSPs).
• the method may further include comparing the concentration of a first assay with concentrations of a second or more assays from the same individual over a period of time or against a standard concentration.
• the marker can an HSP such as HSP 70, HSP 60, HSP 90, gp 96, cpnlO, cpn20, ubiquitin or cpn 30.
• the marker can also be a bacteria such as Staphylococcus aureus, Porphyromonas gingi ⁇ allis, Eikenella corrodens, Actinobacilus actinomycetemcomitans, Prevotella intermedia, Campylobacter rectus, Staphylococcus epidermidis, Salmonella spp., Escherichia coli, Neisseria gonorrhoea, Neisseria meningitis, Mycobacterial tuberculosis, Haemophius influenzae, Pasteurella multocida, B. bronchiseptica, or Fusobacterium nucleatum.
• the marker may be a bacteria produced factor such as endotoxin-LPS, gapstatin, and dermonecrotic toxin (DNT).
• the time between assays may extend over a period, for example, of at least about 12 hours.
• the concentration of HSP is measured using an immunoassay.
• the concentration of HSP is measured using an assay for a nucleotide molecule encoding HSP.
• a method of treating or preventing osteoporosis has been developed.
• a therapeutically effective amount of a formulation which is either an HSP antigenic formulation or a bacterial antigenic formulation.
• the osteoporosis is caused by a bone disease induced by bone infectious agents such as viruses, bacteria, fungi, protozoa or parasites.
• the HSP can be HSP 60, HSP 70, HSP 90, gp 96, cpn 10, cpn 20, ubiquitin, or cpn 30, or combinations thereof.
• the HSP can be further complexed with an antigenic material or formulated in combination with an adjuvant.
• the antigenic material can be a peptide or a protein having an antigenic determinant of a virus, bacteria, fungi, protozoa or parasite that induces a bone disease.
• molecular chaperone describes a number of unrelated proteins that are involved in the assembly and reassembly of proteins and in the transmembrane transport of proteins, for example, from the cytoplasm into the mitochondria. Some of these proteins are referred to as heat shock proteins ("HSPs") or stress proteins.
• HSPs include HSP 70, HSP 70, gp 96, and HSP 100. These HSPs accomplish different kinds of chaperonin functions.
• HSP 70 located in the cell cytoplasm, nucleus, mitochondria, or endoplasmic reticulum, (Lindquist, S., et al., 1988, Ann. Rev.
• HSP 70 located in the cytosol is involved in similar activities.
• GP 96 present in the endoplasmic reticulum is alao involved in antigen presentation (Srivastava, P. K., et al., 1991, Curr. Topics in Microbiology & Immun. 167:109- 123).
• HSPs are essential to both prokaryotic and eukaryotic cells for chaperone function during the intracellular (un)folding, assembly and translocation of proteins.
• HSP expression is elevated in cells undergoing stress, such as those in damaged or inflamed tissue. Conditions as diverse as a rise in temperature, hypoxia, irradiation, infection and exposure to toxic chemicals can all result in increased HSP expression.
• HSP Hemasis protein
• mycobacterial homologue a monopeptide that influences the expression of a protein
• HSPs are very immunogenic.
• the potential of HSPs for inducing autoimmunity has been broadly investigated. However, induction of autoimmunity was not reported in most experimental systems. Rather, in many models of experimental autoimmune diseases, development of resistance to subsequent induction of a disease is a common feature.
• HSPs are constitutive molecules.
• a number of HSPs are well known proteins, including ubiquitin, immunosuppressant-binding proteins and P-glycoprotein.
• HSPs have been reported to induce cell and tissue behavior consonant with their involvement in inflammation.
• HSP 70 and E. coli groEL induce pores in membranes and thus may have similar actions to a wide variety of lysins and haemolysins produced by bacteria.
• HSPs from various bacteria can induce human or murine cells to release a range of pro-inflammatory cytokines.
• HSPs have been directed to develop ways to make use of HSPs. For example, methods of evaluating chronic exposure of a mammal to sublethal levels of pollutants by measuring HSP concentrations have been reported. See, for example, U.S. Patent No. 5,780,246; U.S. Patent No. 5,232,833, both to Sanders, et al. Compositions and methods of vaccinating with HSPs to prevent diseases such as cancers have been developed. See, for example, U.S. Patent Nos. 5,830,464; 5,948,646; and 6,030,618, all to Srivastava.
• an "antigenic molecule” as used herein refers to peptides with which the HSPs are endogenously associated in vivo (e.g., in infected cells) as well as exogenous antigens/immunogens (i.e., with which the HSPs are not complexed in ⁇ i ⁇ o) or antigenic/immunogenic fragments and derivatives thereof.
• Specifically hybridize refers to nucleotide molecules which hybridize with the mRNA transcribed from the gene for the HSP at a stringency condition wherein selected number of base-pair mismatches results in nonhybridization.
• stringency conditions for various hybridization assay formulas depend upon the constellation of temperature, ionic concentration and pH. Generally, for optimal RNA:RNA hybridization, the temperature is inversely related to the salt concentration; the pH should be held in the range of from about 6.9 to about 7.4, e.g., for 15 nucleotide sequences (15-mer). For RNA:DNA hybridizations, similar assay conditions apply but lower temperatures (accompanied by higher salt concentrations) are generally employed than for RNA:RNA hybridizations.
• SDS-PAGE is a common tool for protein analysis.
• Sodium dodecyl sulfate is a detergent that coats proteins with negative charges at a constant charge-to-mass ratio such that in an electric field the proteins would travel at the same velocity in the absence of any separation matrix.
• the smaUer proteins are able to travel faster through the gel to the anode (+) than larger proteins, which encounter more resistance traveling through the gel.
• There are different types of stains that can be used to develop the gel such as Coomassie blue and Silver stain.
• SDS-PAGE is a qualitative tool, in which the rough quantities and sizes of proteins in a sample can be gauged by direct comparison of the band in question to bands of a molecular weight ladder.
• the Agilent BioanalyzerTM is a micro-total analysis system
• p -TAS that uses miniaturized chemical chips with microchannel networks fabricated on glass, quartz, or plastic chips.
• a typical channel is roughly 50 microns wide and 10 microns deep.
• the Agilent BioanalyzerTM Protein 200 Assay was developed to more efficiently characterize proteins by size and concentration in a sample. This microfluidic system functions somewhat analogously to SDS-PAGE, but confers many benefits over the macro-scale analytical method.
• Some advantages of the Protein 200 Assay for the BioanalyzerTM include small sample volumes, higher throughputs of data/sample, reduced resource consumption and waste production, and automation of multi-step processes.
• proteins are denatured with B- mercaptoethanol and fluorescence labeled.
• the proteins are coated with SDS at a constant charge-to- mass ratio.
• Strategically located electrodes create electrokinetic forces capable of moving fluids and separating different sized proteins. The molecules are separated by the amount of charge on the protein. Larger, more negatively charged proteins travel toward the cathode. As labeled protein molecules migrate past a certain point in the channel, their fluorescence is detected by a laser beam.
• the sensitivity of the Protein 200 Assay is known to be affected by salt concentrations in the sample buffer because at higher concentrations smaller amounts of protein are injected into the separation channel. II.
• Bone Densitometry Considerable progress in the development of methods for assessing skeletal bone mass now makes it possible to detect osteoporosis noninvasively and early.
• osteoporosis may be detected after fractures that occur with minimal trauma, as an incidental finding on an x-ray film, or by measurement of BMD by bone densitometry, which is also known as bone density scans.
• Bone density scans are considered by many as an instant snapshot of bone status. These scans, known collectively as BMD tests, are used to detect the amounts of bone mass in the spine, hip, wrist, hand, heel, or the entire body and to evaluate its density.
• Dual energy x-ray absorptiometry can measure soft-tissue composition (lean and fat mass) and bone mass or bone density at the lumbar spine, hip, and forearm, as well as total-body BMD, with greater precision and faster scanning times than the dual- photon absortiometry (Consensus Development Center: "Prophylaxis and treatment of osteoporosis” in Am J Med. 90:107- 101(1991)).
• DEXA is limited by its relatively high equipment cost. The accuracy of this technique has not been fully documented for measuring of all skeletal sites.
• a standard bone mineral report consists of measurements expressed as bone mineral content (the amount of hydroxy apatite, in grams)and converted to area density (grams per square centimeter) within the region of interest.
• normal values are provided according to sex and race and are plotted according to age. Demographic data, including the clinical indications and the patient's age, sex, race, weight, and height, are also considered.
• a region of interest must be selected.
• the sites of measurement should be constant because the bone mineral content varies between different bones and between different regions of the same bone.
• the results are compared with normative values, and standard curves of normative values are provided for individuals of both sexes and several races. Comparison of measured values with mean values for normal young or age- matched individuals permits an assessment of the risk of fracture.
• a normal value for bone mineral content is within 1 standard deviation (SD) of the mean value for young adults of the same age and sex (that is, the t score is more than -1).
• SD standard deviation
• Osteopenia is considered to be present when the value for bone mineral content is more than 1 SD but not more than 2.5 SDS below the mean for young adults (that is, the t score is less than -1 and more than -2.5).
• Osteoporosis is considered to be present when the value is more than 2.5 SDS below the mean bone mineral content for young adults (that is, the t score is less than -2.5) (Kanis et al., 1994).
• Severe osteoporosis is considered to be present when the value for bone mineral content is more than 2.5 SDS below the mean for young adults and there is at least one so-called fragility fracture (assumed to be associated with osteoporosis because it occurred as a result of slight trauma).
• the t score is used for the diagnosis of low bone mass or osteoporosis.
• Physicians should initiate therapy to reduce the patient's risk of fracture on the basis of the presence or absence of risk factors for osteoporosis. Therapy should be initiated to reduce the risk of fracture in women who have a bone mineral density t score of less than -2 in the absence of risk factors and in those who have a t score of less than -1.5 if other risk factors are present.
• Biochemical Markers of Bone Turnover A combination of markers of bone turnover can be used in a variety of ways in the clinical investigation of osteoporosis.
• the rate of postmenopausal bone loss may be determined by biochemical markers, such that a single biochemical assessment shortly after menopause, in conjunction with a bone mass measurement, may be used to identify women with high bone turnover and who are therefore likely to sustain a high rate of bone loss.
• markers may be used to identify the subgroup of patients with high bone turnover who may benefit from a different therapeutic strategy from that used in patients with low bone turnover.
• markers can be used in the clinical investigation of new therapeutic agents to monitor their effect and mechanism of action (Consensus Development Center 1991).
• Osteocalcin is a bone-specific protein secreted by osteoblasts, the bone-forming cells, and its serum level is a sensitive marker of the rate of bone formation.
• Other markers of bone formation include serum levels of total and bone-specific alkaline phosphatase and serum type 1 collagen propeptide.
• Pyridinoline and deoxypyridinoline are collagen cross-links that are released into the blood and urine during the degeneration of type 1 collagen in the process of osteoclastic bone resorption (Delmes "Clinical use of biochemical markers of bone remodeling in osteoporosis," in Osteoporosis Christiansen, et al., (eds). Copenhagen, Osteopress, pp 450-458 1990).
• Urinary excretion of pyridinoline such as hydroxylysylpyridinoline and lysylpyridinoline has been shown to be a more sensitive and specific marker of bone resorption than conventional markers such as urinary hydroxyproline (Uebelhart, et al., Bone Mineral, 8, 87-96 (1990)).
• Plasma tartrate-resistant acid phosphatase is another marker of bone resorption (Delmes, (1990)).
• Radiographic Findings A reduction in bone calcium content must exceed 30% to be observed with certainty on conventional radiographs.
• Staphylococcus aureus contains receptors for fibronectin (Raja, et al., Infect. Immun., 582593-2598 (1990); laminin (Mota, et al., Infect. Immun., 56,1580-1584 (1988)), collagen (Patti, et al., Infect. Immun.
• bacteria directly destroy the noncellular components of bone by liberating acid and proteases
• bacteria promote cellular processes that stimulate the degradation of bone or
• bacteria inhibit the synthesis of bone matrix may be either a direct effect of components released by bacteria or a consequence of the induction of host factors, for example, cytokines or prostaglandins that then act on bone cells.
• Mechanisms implicated in the pathology of dental caries are hkely to be only a minor mechanism in skeletal bone pathology.
• endotoxin-LPS has also been reported to inhibit bone collagen and noncoliagenous protein synthesis (Millar, et al., Infect. Immun., 57,302-306 (1986)).
• a number of reports have suggested that extracts of dental plaque or of cultured periodontopathic bacteria can inhibit bone matrix synthesis (Hopps, et al., Periodontal disease: pathogens and host immune response. Hamada, et al., eds., (Quintessence Publishing Co., Ltd., Tokyo) pp. 307-320 (1991); Multanen, et al., J. Clin. Periodontol. 1:729-739 (1985)).
• gapstatin acts only on cells in S phase. This molecule may act by inhibiting the synthesis of cyclin Bl, a protein required to ensure that cells make the transition from G2 to mitosis. As bone remodeling and matrix synthesis require the continued production of osteoblasts and osteoclasts, the action of gapstatin could inhibit new bone matrix formation. Such an effect would be particularly damaging if it were to occur in concert with molecules stimulating bone breakdown, such as cpn60. It is possible that gapstatin could inhibit the formation of osteoclasts.
• Bordetella bronchiseptica produces a 145 kDa dermonecrotic toxin DNT) that is responsible for turbinate atrophy in swine atrophic rhinitis (Ackerman et al., 1991; Dunan et al., 1966). Histologically, the lesions induced by B. bronchiseptica suggest impaired osteoblastic function (Silveira et al., 1982). There is one report of the effect of DNT on cultured bone, and its effects were not particularly striking (Kiman et al., 1987).
• Hsp heat shock proteins
• the human protein has 50% sequence identity with the mycobacterial homologue, with a further 20% conservative substitutions, causing several areas in the human molecule to be fully identical to the bacterial protein.
• the best studied molecular chaperones are the chaperonins
• cpns consist of two interacting oligomeric proteins known as cpnlO and cpn60 (from the molecular masses of their subunits).
• the cpns form heptameric structures with protein folding occurring within the cavity of the cpn60 oligomer, a process requiring heptameric cpnlO.
• the Hsp70 family of molecular chaperones act as monomers.
• the Hsp90 family is one of the most abundant proteins in unstressed eukaryotic cells and this dimeric protein interacts with a large number of intraceUular proteins, most notably the steroid receptors.
• Hsp47 is known to be a collagen molecular chaperone (Laemmli, 1970). Certain of the molecular chaperones cpn60, Hsp70, and Hspl04, bind and hydrolyze adenosine trip hosp hate.
• tissues or cells are generally sampled under conditions which do not elevate HSP levels. The method of tissue or cell sampling, HSP isolation and measurement, and formation of HSP complexes are described by U.S. Patent Nos. 5,232,833 and 5,780,246 to Sanders, incorporated herein by reference.
• Representative bone samples can be obtained from a qualified bone bank.
• the sample pool is then characterized to generate a database based on measurements of bone density.
• Many bone density techniques have shown clinical utility for assessing fracture risk.
• Some devices offer advantages in terms of versatility (i. e., the number of skeletal sites that can be measured), ability to monitor response, cost, availability, and ease of use (Table 2).
• Table 2 Comparison of Bone Densitometry Techniques
• a SXA single X-ray absorptiometry
• DXA dual X-ray absorptiometry
• pDXA peripheral dual X-ray absorptiometry
• QCT quantitative computed tomography
• pQCT peripheral quantitative computed tomography
• QUS quantitative ultrasonography
• BMD bone mineral density
• Percentage scores are determined with respect to either the age-matched normal BMD (AMN) or the young normal BMD (YN) using the following equations:
• the densitometry analysis software can calculate these percentage values.
• the standard deviation (SD) scores are also usually provided by the densitometry software.
• the age- matched SD score is commonly referred to as the "Z-score,” whereas the young normal standard deviation score has been labeled the "T-score.”
• Z-score The age- matched SD score
• T-score the young normal standard deviation score
• different densitometry systems may have different names for these parameters.
• the age-matched or Z-score is calculated as the difference between the patient's BMD and the normal BMD for those of the same age, sex, and race (AMN), divided by the SD of the normal population. This is calculated by the densitometry system using the following equation:
• BMD difference is expressed in terms of the YN bone density:
• the WHO has defined the following criteria for the assessment of osteoporosis based on a BMD measurement at any skeletal site.
• All bone samples can be harvested in sterile saline, centrifuged, washed briefly in saline, and lyophihzed. Chaperone molecules are removed from the various bacteria by, for example, by gentle saline extraction as described by Wilson et al., (1985). Briefly, bone samples are suspended in sterile saline and stirred gently at 4°C for 1 h. The debris is then removed by a means such as centrifugation and the soluble components are dialyzed extensively against distilled water and lyophihzed. The protein content of the BS can be determined by a method such as described by Lowry, et al., J. Biol. Chem.
• the carbohydrate content can be determined by a method such as described by Dubois, et al., Anal. Chem. 28:350-356 (1956), and the nucleic acid content by absorption at 260/280 run.
• the LPS content can be measured using a commercial chromogenic Limulus amebocyte lysate assay, such as one market by Pyrogent, Byk-Mallinckrodt, London, UK, according to the manufacturer's instructions.
• the components of the BS can be analyzed by for example SDS- PAGE using 12% gels according to a method such as one described by Laemmli, et al., Nature (Lond.) 227:680-685 (1970).
• Samples can be diluted to an appropriate extent such as 1:1 with sample buffer and boiled for a period such as 5 min. before loading.
• Gels can be run using for example a MiniProtean II system (Bio Rad Laboratories) and stained with for example Coomassie brilliant blue (Sigma Immunochemicals).
• the molecular weight markers can be based on Dalton standards (Sigma Immunochemicals) or any other standards which one of ordinary skill in the art can recognize.
• Gels can also be silver stained using a commercial kit such as one marketed by Gelcode® mark silver stain kit; Pierce, Rockford, IL, to detect both the presence of protein and carbohydrate.
• Two-dimensional PAGE Two-dimensional PAGE
• Two-dimensional PAGE gels can be run using a method such as one described by O'Farrell, et al, J. Biol. Chem. 250:4007-4021 (1975). Gels can be run using for example a MiniProteanTM II system and stained with, for example, Coomassie blue, with similar molecular weight markers as above.
• the first dimension, isoelectric focusing can be over a pH range of 1-14, preferably 3-10.
• Second dimension separation can be carried out by, for example, molecular mass separation using a 12%SDS-PAGE gel.
• Bound test-antibody (anti-mouse) IgG can be detected using for example peroxidase labeled goat anti-mouse IgG (gamma- chain specific) (Sigma Immunochemicals) at 1:1,000 in PBS-T2% FCS. After a final wash, the blots can be developed with a solution such as 1 mg/ml 3,3 prime-diaminobenzidine tetrahydrochloride (Sigma Immunochemicals) in 50 mM Tris (Sigma Immunochemicals), pH 7.6, containing 150 mM NaCl (BDI-I) and 0.05% hydrogen peroxide (Sigma Immunochemicals). Each reaction can be terminated by extensive rinsing with distilled water. Protein purification
• Crude BS can be fractionated using column chromatography such as fractionation at 4°C on a Q-SepharoseTM anion exchange column (50 cm times 1.6 cm).
• the column can be equilibrated in a solution such as 20 mM Tris-HCl, pH 8.5 (buffer A).
• the BS (generally 100-400 mg) can be loaded on in the same buffer.
• the column can be washed with a solution such as 500 ml of buffer A and then eluted with for example 1,000 ml linear gradient of O-2 M NaCl in buffer A. Fractions can be collected, whose absorbance can be monitored at 280 nm.
• the location of the osteolytic chaperone protein can be determined by a combination of activity assay, for example, SDS-PAGE, and the Western blot analysis. Fractions containing osteolytic activity can be dialyzed against for example deionized water to remove salt and lyophihzed. The fraction with the highest specific activity and the least number of protein bands on SDS-PAGE can then be further fractionated at room temperature on a second column such as an anion exchange column.
• activity assay for example, SDS-PAGE
• Western blot analysis Fractions containing osteolytic activity can be dialyzed against for example deionized water to remove salt and lyophihzed. The fraction with the highest specific activity and the least number of protein bands on SDS-PAGE can then be further fractionated at room temperature on a second column such as an anion exchange column.
• the purity of the fractions can again be assessed, visually by SDS-PAGE or using another means recognizable by one of ordinary skill in the art, and 100 pg of the cleanest fraction can be dialyzed against 50 mM of Tris but&, pH 7.6, containing 10 mM KCl and 10 mM MgC12 (buffer C).
• This sample can be run on for example a 5- ml ATP-SepharoseTM (Sigma Immunochemicals) column.
• the column can be washed with buffer C and bound protein eluted in 5 mM ATP (Sigma Immunochemicals), also in buffer C. Protein can be located by SDS-PAGE and visualized using a silver stain kit (Sigma Immunochemicals).
• Gel filtration can be used to determine the molecular mass range of the osteolytic chaperone protein isolated by a method such as ATP-affinity chromatography. This can be achieved by running the purified protein on a column such as Bio-Sil TSK250 (Bio Rad Laboratories) column in a buffer such as 0.1 M sodium phosphate buffer, pH 6.7, and measuring the absorption of the collected fractions at a wavelength in the range between 205 and 280 nm. Data analysis and correlation to clinical outcome variables
• the experimental findings and clinical bone densitometry and Q-CT measurements can be documented using, for example, a standardized relational computer database using a numerical code system.
• the computer program SPSS/PC+9.0 SPSS Inc., 44 N. Michigan Ave., Chicago, IL 60611
• Descriptive statistics of the raw data can be carried out using frequency tables. Normal distribution can be determined by fitting to normality and by obtaining normal probabihty plots, where the ranked observed residuals (deviation from the mean) are plotted on the x-axis against the standardized values of the normal distribution on the y-axis. Normal distribution can then be indicated if the observed residuals fall onto the straight line.
• these tables yield a cell frequency, i. e. the number of cases in the patient population that had this particular combination.
• a cross tabulation method allows to evaluate the reliability of the test of these relationships.
• the presence of osteopenia, age, gender, other contributing factors such as medical conditions are categorical variables.
• Multiple simultaneous relations and interactions between the variables of the multipleway frequency table can be examined on the basis of log-linear equations, which allow computation of the cell frequencies that would have been expected if the variables involved were unrelated. This can be performed using for example an iterative proportional fitting procedure.
• significant deviations of the observed from the expected frequencies can reflect a statistically significant relationship between a specific chaperone molecule and osteopenia.
• the residual frequencies can be calculated by subtracting the expected frequencies from the observed frequencies. If no relationship exists, all residual frequencies are expected to consist of positive and negative values of similar magnitude and to be evenly distributed across the cells of the frequency table. Plotting the residuals is therefore used as another means of assessing correlations between the presence of chaperone molecules with osteopenia. In all statistical tests employed in this study, a significance level such as one of p ⁇ 0.05 can be chosen. One of ordinary skill in the art can choose a proper significance level. IV. Diagnosing Osteoporosis using Bacterial and/or Molecular Chaperon Markers
• the method of diagnosing osteoporosis disclosed herein generally includes 1) samphng the tissue or cells of a mammalian subject, 2) measuring the level of a marker and 3) designating the mammalian subject as having osteoporosis if the level of the marker is higher than a standard level of the marker in a member of a control group.
• the method may optionally include a step of isolating the marker.
• the control group is selected according to factors such as geographical location, gender and/or age.
• the mammalian subject is a human being.
• the mammalian subject is a postmenopausal female.
• the marker can be either a bacteria, a bacteria produced factor, or a chaperon molecule. In one embodiment, the marker is a bacteria.
• Representative bacterial markers are: Actinobacillus actinomycetemcomitans, Porphyromonas gingivallis, Eikenella corrodens , Fusobacterium nucleatum, Prevotella inter-media, Campylobacter rectus, Staphylococcus aureus, Staphylococcus epidermidis, Salmonella spp., Escherichia coli, Neisseria gonorrhoea, Neisseria meningitis, Mycobacterial tuberculosis, Haemophius infruenzae, Pasteurella multocida.
• the marker can be a chaperon molecule.
• HSP 70 HSP 70, gp 96, cpnlO, and cpn20, alone or in combination.
• the marker is a human HSP.
• the marker can be a bacteria produced factor such as endotoxin-LPS, gapstatin, or dermonecrotic toxin (DNT).
• HSP Reagents Preparation and Purification of HSP Reagents
• the complexes can be intracellularly produced complexes having HSPs from a selected recombinant host cell and antigenic peptides expressed from cDNAs of a diseased bone or tissue cell; the antigenic peptides of the complex are thus representative of antigenic peptides found in such bone cell.
• the methods of preparing HSP complexes include the steps of obtaining (e.g., isolating) diseased bone or other tissue cells from one or more individuals, preparing RNA from the cells, making cDNA from the RNA, introducing the cDNA into host cells, culturing the host cells so that the diseased bone cell-derived cDNAs are expressed, and purifying HSPs-peptide complexes from the host cells.
• the cDNA prepared from disease bone or tissue cell RNA herein referred to as "diseased bone cDNA" is optionaUy amplified prior to introduction into a host ceU for expression.
• the cDNAs are optionally inserted into a cloning vector for replication purposes prior to expression.
• the cDNAs are inserted into an expression vector or intrachromosomally integrated, operatively linked to regulatory element(s) such as a promoter, for purposes of expressing the encoded proteins in suitable host cells in vitro.
• the cDNAs are introduced into host cells where they are expressed by the host cells, thereby producing intracellularly noncovalent complexes of HSPs and peptides.
• the recombinant host cells can be cultured on a large scale for production of large amounts of the immunogenic complexes.
• the diseased bone cDNA library can be stored for future use (e.g., by lyophilization or freezing), or expanded by replication in a cloning vector in suitable host cells to meet increased demand for the immunogenic complexes.
• the immunogenic compositions prepared from the host cells expressing the diseased bone cDNAs comprise complexes of HSPs of the host cell noncovalently associated with peptides, inter alia, those derived from the diseased bone cells from which the RNA was originally derived.
• Such complexes can induce an immune response in a patient against the diseased bone cells that is therapeutically or prophylactically efficacious.
• the patient is the subject from whom the diseased bone cells used to make cDNA were obtained.
• the diseased bone ceUs can be from one or more subjects different from the patient but having diseased bone of the same tissue type.
• host ceUs for expression of the diseased bone cDNAs can also be genetically engineered to coexpress recombinantly one or more HSP genes so that increased amounts of complexes comprising immunogenic peptides noncovalently associated with a HSP can be produced.
• the HSP-antigenic molecule complex is autologous to the individual; that is, the complex is isolated from either the infected cells of the individual himself (e.g., preferably prepared from infected tissues of the patient). Alternatively, the complex is produced in vitro (e.g., wherein a complex with an exogenous antigenic molecule is desired). Alternatively, the HSP and/or the antigenic molecule can be isolated from the individual or from others or made by recombinant production methods using a cloned HSP originally derived from the individual or from others.
• Exogenous antigens and fragments and derivatives (both peptide and non-peptide) thereof for use in complexing with HSPs can be selected from among those known in the art, as well as those readily identified by standard immunoassays known in the art by the ability to bind antibody or major histocompatibility molecules (MHC molecules) (antigenicity) or generate immune response (immunogenicity).
• MHC molecules major histocompatibility molecules
• Complexes of HSPs and antigenic molecules can be isolated from infected tissue of a patient, or can be produced in vitro (as is necessary in the embodiment in which an exogenous antigen is used as the antigenic molecule).
• the HSP-antigenic molecule complex that is administered to the patient can be the same or different from the HSP-antigenic molecule complex used to sensitize the APC that are administered to the patient.
• the APC and purified HSP-antigenic molecule complexes can be present in a single composition, or different compositions, for administration.
• HSPs that can be used include but are not limited to, HSP
• the HSPs are human HSPs.
• the HSPs can be allogeneic to the patient, in a preferred embodiment, the HSPs are autologous to (derived from) the patient to whom they are administered.
• the HSPs and/or antigenic molecules can be purified from natural sources, chemically synthesized, or recombinantly produced.
• the immunogenic HSP-peptide complexes disclosed herein may include any complex containing an HSP and a peptide that is capable of inducing an immune response in a mammal.
• the peptides are preferably noncovalently associated with the HSP.
• Preferred complexes may include, but are not hmited to, HSP 60- peptide, HSP 70-peptide and HSP 70-peptide complexes.
• an HSP called gp 96 which is present in the endoplasmic reticulum of eukaryotic cells and is related to the cytoplasmic HSP 70s can be used to generate an effective vaccine containing a gp 96-peptide complex.
• compositions comprising HSP noncovalently bound to antigenic molecules can be administered to elicit an effective specific immune response to the complexed antigenic molecules (and not to the HSP).
• the HSP-antigenic molecule complexes are preferably purified to at least 70%, 80% or 90% of the total mg protein.
• the HSP-antigenic molecule complexes are purified to apparent homogeneity, as assayed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
• Immunogenic or antigenic peptides that are endogenously complexed to HSPs or MHC antigens can be used as antigenic molecules for treating and/or preventing bone diseases.
• such peptides may be prepared that stimulate cytotoxic T cell responses against different viral proteins including, but not limited to, proteins of immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), hepatitis type A, hepatitis type B, hepatitis type C, influenza, VariceUa, adenovirus, herpes simplex type I (HSV-I), herpes simplex type II (HSV-II), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, papova virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, coxsackie virus, mumps virus, measles virus, rubella virus and polio virus.
• HSV-I immunodeficiency virus type I
• HSV-II human immunodeficiency virus type II
• hepatitis type A hepatitis
• the HSP-antigenic molecule complex to be used is a complex that is produced in vivo in cells.
• HSPs can be purified for such use from the endogenous HSP-peptide complexes in the presence of ATP or low pH (or chemically synthesized or recombinantly produced). The procedures for purification of HSPs and their respective complexes are described in the Srivastava patents.
• HSP-peptide complexes may be isolated from any eukaryotic cells for example, tissues, isolated cells, or immortalized eukaryote cell lines infected with a preselected intracellular pathogen.
• eukaryotic cells for example, tissues, isolated cells, or immortalized eukaryote cell lines infected with a preselected intracellular pathogen.
• Exogenous antigens or antigenic portions can be selected for use as antigenic molecules, for complexing to HSPs, from among those known in the art or determined by immunoassay to be able to bind to antibody or MHC molecules (antigenicity) or generate immune response (immunogenicity).
• immunoassays known in the art can be used, including but not limited to competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in vivo immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, immunoprecipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc.
• ELISA enzyme linked immunosorbent assay
• sandwich immunoradiometric assays immunoradiometric assays
• gel diffusion precipitin reactions immunodiffusion assays
• immunodiffusion assays in
• antibody binding is detected by detecting a label on the primary antibody.
• the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody.
• the secondary antibody is labelled.
• Many means are known in the art for detecting binding in an immunoassay and are envisioned for use.
• T cell-mediated responses can be assayed by standard methods, e.g., in vitro cytoxicity assays or in ⁇ i ⁇ o delayed-type hypersensitivity assays.
• Potentially useful antigens or derivatives thereof for use as antigenic molecules can also be identified by various criteria, such as the antigen's involvement in neutralization of a pathogen's infectivity (wherein it is desired to treat or prevent infection by such a pathogen) (Norrby, 1985, Summary, in Vaccines 85, Lerner, et al. (eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., pp. 388-389), type or group specificity, recognition by patients' antisera or immune cells, and/or the demonstration of protective effects of antisera or immune cells specific for the antigen.
• the antigen's encoded epitope should preferably display a small or no degree of antigenic variation in time or amongst different isolates of the same pathogen.
• molecules comprising epitopes of known viruses are used, as discussed above.
• molecules comprising epitopes of known bacteria are used, as discussed above.
• molecules comprising epitopes of known protozoal infections of bone are used.
• antigenic epitopes may be prepared from protozoa including, but not limited to, leishmania, kokzidioa, and trypanosoma.
• protozoa including, but not limited to, leishmania, kokzidioa, and trypanosoma.
• molecules comprising epitopes of known parasites are used.
• antigenic epitopes may be from parasites including, but not hmited to, chlamydia and rickettsia.
• Osteoporosis caused by infectious diseases of bone that can be diagnosed using a chaperon molecule marker can be caused by bone infectious agents including, but not limited to, viruses, bacteria, fungi, protozoa and parasites, as discussed above.
• the method of treating osteoporosis disclosed herein generally includes administering to a mammalian subject a drug composition effective to treat the infectious agent causing the osteoporosis.
• the drug composition generally contains a drug and optionally a drug delivery carrier and/or one or more biocompatible excipients.
• Exemplary drug delivery carriers are liposomes, micro or nanoparticles formed of natural or biodegradable synthetic polymers such as polylactic acid, polyglycolic acid, polyhydroxyalkanoates, natural or chemically modified starches, chitosan, and proteins such as gelatin.
• the marker for osteoporosis is a chaperon molecule such as a HSP
• the drug composition can include one or more complexes formed of the HSP with another molecule.
• the therapeutic reagents can be essentially the same as the diagnostic reagents, purified and prepared according to GMP standards. Modes of administration include but are not limited to subcutaneously, intramuscularly, intravenously, intraperitoneally, intradermally or mucosally.
• the therapeutic regimens and pharmaceutical compositions disclosed herein may be used with additional immune response enhancers or biological response modifiers including, but not limited to, the cytokines IFN-. alpha., IFN-. gamma., IL-2, IL-4, IL- 6, TNF, or other cytokine affecting immune cells.
• additional immune response enhancers or biological response modifiers including, but not limited to, the cytokines IFN-. alpha., IFN-. gamma., IL-2, IL-4, IL- 6, TNF, or other cytokine affecting immune cells.
• the complexes of the HSP and antigenic molecule are administered in combination therapy with one or more of these cytokines.
• HSP-antigenic molecule complexes may be administered using any desired route of administration.
• Advantages of intradermal or mucosal administration include use of lower doses and rapid absorption, respectively.
• Advantages of subcutaneous or intramuscular administration include suitability for some insoluble suspensions and oily suspensions, respectively.
• Mucosal routes of administration include, but are not hmited to, oral, rectal and nasal administration. Preparations for mucosal administrations are suitable in various formulations as described below.
• the complex may be formulated in an appropriate buffer, for example, phosphate buffered saline or other physiologically compatible solutions, preferably sterile.
• an appropriate buffer for example, phosphate buffered saline or other physiologically compatible solutions, preferably sterile.
• the resulting complex may be formulated with a non-ionic surfactant such as Tween, or polyethylene glycol.
• the compounds and their physiologically acceptable solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral, or rectal administration.
• the pharmaceutical preparation may be in liquid form, for example, solutions, syrups or suspensions, or may be presented as a drug product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, ceUulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non- aqueous vehicles (e.g., almond oil, oily esters, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p- hydroxybenzoates or sorbic acid).
• suspending agents e.g., sorbitol syrup, ceUulose derivatives or hydrogenated edible fats
• emulsifying agents e.g., lecithin or acacia
• non- aqueous vehicles e.g., almond oil, oily esters, or fractionated vegetable oils
• compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disinte grants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
• binding agents e.g., pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose
• fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
• lubricants e.g., magnesium stearate, talc or silica
• disinte grants e.g., potato starch
• Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
• compositions may take the form of tablets or lozenges formulated in conventional manner.
• the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
• Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
• the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
• the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
• the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
• the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
• the compounds may be formulated with suitable polymeric or hy drop hob ic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• suitable polymeric or hy drop hob ic materials for example, as an emulsion in an acceptable oil
• ion exchange resins for example, as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophilic drugs.
• the compounds for use can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
• a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
• a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
• a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
• Osteoporosis caused by bacterial infection or bone diseases can be treated by immunizing by administering to a mammalian subject an immunogenic composition.
• the immunogenic composition may comprise an attenuated or modified infectious agent.
• the immunogenic composition may include a HSP. Immunization to bone diseases by HSPs are well documented. For example, in rat adjuvant arthritis (AA), resistance could be induced by immunization with mycobacterial HSP 60 in incomplete Freund's adjuvant (IFA). Similar findings were obtained with mycobacterial and Escherichia coli HSP 70 and HSP10, and DNA vaccination with mycobacterial HSP 60 was also protective. Bardwell, J. C. A., et al., Proc. Natl.
• Preimmunization using HSP 60 has been found to induce resistance to autoimmunity in other arthritis models, such as streptococcal cell-wall-induced arthritis-8 and, importantly, nonmicrobially induced models such as avridine-9 (a synthetic nonimmunogenic hpoidal amine) or pristane-induced arthritis, as well as collagen-induced arthritis.
• other arthritis models such as streptococcal cell-wall-induced arthritis-8 and, importantly, nonmicrobially induced models such as avridine-9 (a synthetic nonimmunogenic hpoidal amine) or pristane-induced arthritis, as well as collagen-induced arthritis.
• EAE experimental autoimmune encephalomyelitis
• NOD nonobese diabetic mice
• Such suppressive activity is effective in conditions as diverse as CD4 + T helper 1 (Thl)-mediated chronic joint inflammation and the primarily CD8 + T-cell-mediated destruction of insulin-producing T-cells.
• recognition of self-HSP molecules can be an important immunological strategy that contributes to establishment or maintenance of self-tolerance. The same can be true in the case of inflammation caused by infection, allowing one to logically conclude that the T-cell response to HSPs operates in the control and downmodulation of inflammatory responses, irrespective of their origin.
• HSPs in Arthritis Patients Immune reactivity toward HSPs has been extensively investigated. For example, when monitoring T-cell proliferative responses to HSP 60 in children with juvenile rheumatoid arthritis (JRA), responses were found to be present exclusively in patients with spontaneously remitting oligoarticular forms (OA- JRA) of the disease but not in patients with progressive (polyarticular or systemic) forms of the disease. Such responses showed a pattern of fluctuation that suggested they coincided with development of remission, i.e. with disease suppression.
• JRA juvenile rheumatoid arthritis
• HSP 60-reactive T cells The majority of such HSP 60-reactive T cells has been found to respond not only to the mycobacterial HSP 60 molecule but especially to the human HSP 60. The presence of such Th2-type cells in the self-remitting forms of the disease suggests the protective nature of these T cells in humans.
• RA rheumatoid arthritis
• HSPs have unique characteristics which seem to give HSPs a critical immunological status, especially their stress-dependent differential expression. Although strong constitutive expression of HSP 60 has been shown in the thymic medullary epithelium, peripheral T-cell responses to self-HSP are abundant. Thus, self- HSP-specific T cells are probably positively selected and subsequently escape from negative selection, suggesting their receptor has a low affinity for the self-HSP molecule. In the periphery, the level of constitutive expression of HSPs, such as HSP 60, is low and peripheral tolerance for these self-antigens is likely to be less tight than for other, more abundantly available, self-proteins. Under conditions of inflammatory stress, HSP synthesis is grossly upregulated, providing the immune system with a target through which to monitor and control dangerous or potentiaUy deleterious inflammatory conditions.
• HSPs Several of the characteristic features of HSPs are important. First, their unique degree of evolutionary conservation provides the molecular basis for the demonstrated crossrecognition of microbial and self-HSP by immune ceUs. Second, microbial HSPs are highly immunogenic and healthy individuals have self-HSP- reactive T cells. Third, HSPs in any cell type, everywhere in the body, respond to a stress by immediate upregulation. Although some of these features may individuaUy be true for other proteins in nature, the combination of the three features are unique for HSPs.
• a number of possible mechanisms may contribute to the regulatory phenotype of self-HSP-reactive T cells at sites of inflammation. Such mechanisms are proposed to be related to the peripheral tolerance mechanisms that are responsible for the persistence and safe containment of self-HSP-reactive T ceUs in the immune system.
• self-HSP-specific T cells will simply ignore self-HSP molecules. Only after exposure to microbial HSP, in infection or at the gut mucosa, will these T cells with cross-specificity for conserved microbial HSP epitopes be stimulated and expanded.
• anergic T cells generated with antigen in the absence of professional APCs, exerted bystander suppression on the proliferative responses of other T cells in the presence of APC, provided the antigen recognized by the anergic cell was present in the culture.
• HSPs this could mean that quiescent HSP-specific T cells focus their regulatory activity to sites of inflammation where HSPs become temporarily overexpressed. During infection, the activity of such anergic regulators would be outweighed by a dominant frequency of T cells responding
• a third possibility is that self-HSP epitopes are perceived by T cells as APLs or closely related 'partial agonistic' variants of 'full agonist' microbial HSP epitopes.
• APLs do not fully activate T cells but do have the capacity to trigger certain effector functions such as the production of regulatory cytokines. This could be a profitable strategy in the case of HSPs, since exposure to full agonist microbial HSP epitopes in the gut or during infection would expand the self-HSP or APL-oriented (regulatory) repertoire.
• upregulated self- HSP would serve as the APL inducing a regulatory phenotype in HSP-reactive cells.
• APLs in general may have unpredictable and diverse effects, the fact that in this model the APL-like self-HSP is supposed to be involved in thymic positive selection, generating T cells that have only low affinity interaction with the APL, may give direction (regulatory) to this specific type of APL.
• the osteolytic activity of groEL was inhibited by indomethacin and the natural antagonist of interleukin-1 receptor antagonist (IL-lra) but was unaffected by neutralization of tumor necrosis factor (TNF) or inhibition of 5-lipoxygenase.
• IL-lra interleukin-1 receptor antagonist
• TNF tumor necrosis factor
• Mammalian molecular chaperones of molecular mass 27, 47, 70, and 90 kDa were also tested and, with the exception of the 47 kDa protein, all showed activity in the murine calvarial assay.
• Molecular chaperones appear, therefore, to have the capacity to modulate the cellular processes in bone explant cultures, resulting in resorption of the calcified matrix.
• the methods of treating bone diseases using HSP complexes disclosed herein also encompass adoptive immunotherapy.
• the HSP complexes can be used to sensitize antigen presenting cells ("APC") and/or macrophage cells.
• APC antigen presenting cells
• the methods of using Hps complexes to sensitize macrophage and/or APC have been described by U.S. Patent No. 5,985,270 to Srivastava.
• the method of adoptive immunotherapy as disclosed therein is thus fully incorporated herein by reference.
• the APC can be selected from among those antigen presenting cells known in the art, including but not limited to macrophages, dendritic cells, B lymphocytes, and a combination thereof, and are preferably macrophages.
• the HSP complex-sensitized APC may be administered concurrently or before or after administration of the HSP-antigenic molecule complexes.
• Adoptive immunotherapy disclosed herein allows activation of antigen presenting cells by incubation in vitro with HSP-antigenic molecule complexes. Preferably, prior to use of the cells in vivo, measurement of reactivity against the bone infectious agent in vitro is done. This in vitro boost followed by clonal selection and/or expansion, and patient administration constitutes a useful therapeutic/prophylactic strategy.
• the methods of treating and/or preventing osteoporosis include eliciting an immune response in an individual in whom the treatment or prevention of osteoporosis is desired by administering to the mammalian subject a composition which includes an effective amount of an anti-bacteria composition or a HSP complex.
• the HSP complex is essentially an HSP noncovalently bound to an antigenic molecule using any convenient mode of administration in combination with the adoptive immunotherapy methods disclosed herein. Modes of administration include but are not limited to subcutaneously, intramuscularly, intravenously, intraperitoneally, intradermally or mucosally.
• Drug doses are provided in milligrams per square meter of body surface area because this method rather than body weight achieves a good correlation to certain metabolic and excretionary functions (Shirkey, H. C, 1965, JAMA 193:443). Moreover, body surface area can be used as a common denominator for drug dosage in adults and children as well as in different animal species as indicated below in Table 1 (Freireich, E. J., et al., 1966, Cancer Chemotherap. Rep. 50:219-244).
• Dosages of the purified complexes of HSPs and antigenic molecules used for administration are preferably much smaller than the dosages estimated by the prior art methods described above.
• an amount of HSP 70- and/or gp 96- antigenic molecule complexes is administered subcutaneously that is in the range of about 10 micrograms to about 600 micrograms for a human patient, the more preferred human dosage being the same as used in a 25 g mouse, i.e., in the range of 10-100 micrograms.
• the preferred dosage for HSP-90 peptide complexes in a human patient provided by the methods disclosed herein is in the range of about 50 to 5,000 micrograms, the more preferred dosage being 100 micrograms.
• an amount of HSP 70- and/or gp 96-antigenic molecule complexes is administered intradermally or mucosally that is in the range of about 0.1 micrograms to about 60 micrograms for a human patient.
• the therapeutically effective amount of HSP 70- and/or gp 96- antigenic molecule complexes is less than 10 micrograms, e.g., in the range of 0.1 to 9 micrograms; the preferred human dosage being substantially equivalent to or smaller than the dosage used in a 25 g mouse, e.g., in the range of 0.5 to 2.0 micrograms.
• the preferred dosage for HSP 70-antigenic molecule complexes for intradermal or mucosal administration to a human patient is in the range of about 5 to 500 micrograms.
• the therapeutically effective amount of HSP 70-antigenic molecule complexes is less than 50 micrograms, e.g., in the range of 5 to 49 micrograms; the preferred dosage being in the range of 5 to 40 micrograms.
• the dosages are administered every other day for a total of five injections.
• the doses red above are given once weekly for a period of about 4 to 6 weeks, and the mode of administration is preferably varied with each administration.
• each site of administration is varied sequentially.
• the first injection may be given intradermally on the left arm, the second on the right arm, the third on the left belly, the fourth on the right belly, the fifth on the left thigh, the sixth on the right thigh, etc.
• the same site may be repeated after a gap of one or more injections.
• spht injections may be given.
• half the dose may be given in one site and the other half in another site on the same day.
• the mode of therapy can be sequentially varied, e.g., HSP-antigenic molecule complexes may be administered at one time and HSP-antigenic molecule-sensitized APC another time.
• HSP-antigenic molecule complexes may be administered concurrently with HSP-antigenic molecule-sensitized APC.
• the APC and complexes are administered to the patient within 1 week of each other.
• Kits of the compositions disclosed herein include in a first container a pharmaceutical composition comprising a complex of a HSP noncovalently bound to an antigenic molecule and a pharmaceutically acceptable carrier; and in a second container antigen presenting cells.
• HSP-antigenic molecule complexes may be formulated into pharmaceutical preparations for administration as described above.
• Compositions may include a compound formulated in a compatible pharmaceutical carrier prepared, packaged, and labeled for treatment of the indicated bone infectious disease.
• pharmaceutical compositions may be formulated for treatment of appropriate bone infectious diseases.
• compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
• the pack may for example comprise metal or plastic foil, such as a blister pack.
• the pack or dispenser device may be accompanied by instructions for administration.
• kits for carrying out the therapeutic regimens disclosed herein comprise in a first one or more containers therapeutically or prophylactically effective amounts of the HSP-antigenic molecule complexes, preferably purified, in pharmaceutically acceptable form; and in a second container the sensitized APC, preferably purified.
• the HSP-antigenic molecule complex in a vial of a kit may be in the form of a pharmaceutically acceptable solution, e.g., in combination with sterile saline, dextrose solution, or buffered solution, or other pharmaceutically acceptable sterile fluid.
• the complex may be lyophihzed or desiccated; in this instance, the kit optionally further comprises in a container a pharmaceutically acceptable solution (e.g., sahne, dextrose solution, etc.), preferably sterile, to reconstitute the complex to form a solution for injection purposes.
• a kit disclosed herein further comprises a needle or syringe, preferably packaged in sterile form, for injecting the complex, and/or a packaged alcohol pad. Instructions are optionally included for administration of HSP- antigenic molecule complexes by a clinician or by the patient.
• the methods and the compositions and the use thereof an be better understood by the following non-limiting examples.
• Example 1 The methods and the compositions and the use thereof an be better understood by the following non-limiting examples.
• the samples were analyzed using first SDS-PAGE, then the Protein 200 Assay on the Agilent 2 100 Bioanalyzer. Some samples that did not produce satisfactory results (often indicated by a missing upper marker) were desalted and rerun on the Bioanalyzer. Samples were desalted by using YM-3 Centricon tubes spun at 4200x g for approximately 1.5 hours. The Centricon filters were inverted and spun at lOOOx g for 3 minutes. The samples were reconstituted to their original volume with 22 mM Tris, Results
• a SDS-PAGE was conducted on bone extracts from a control healthy patient.
• Slab gel electrophoresis of samples against a ladder of known proteins suggested good separation.
• the Protein 200 assay was then used with the Bioanalyzer with a series of extracts. The results show the stronger presence of bands in the 45-65 kDa range for samples obtained from compromised patents. Because the presence of salts is known to interfere with the assay and that the extracts used in this study were produced in phosphate buffer saline solution, a follow-up experiment was designed to address the potential salt problem. First, a filtration step was added to remove salts from the samples. Furthermore, extraction was conducted with deionized water, instead of with PBS. The changes yielded an improved separation, and the upper marker became visible in some of the samples.
• Crude BS will be fractionated at 4" C on a Q-Sepharose anion exchange column (50 cm times 1.6 cm).
• the column will be equilibrated in 20 mM Tris-HCl, pH 8.5 (buffer A), and the BS (generally 100400 mg) will be loaded on in the same buffer.
• the column will be washed with 500 ml of buffer A and then eluted with a 1,000-ml linear gradient of 0-1 M NaCl in buffer A.
• Ten-ml fractions will be collected, and the absorbence at 280 nm will be monitored.
• the location of the osteolytic chaperone protein will be determined by a combination of activity assay, SDS-PAGE, and the Western blot analysis.
• Fractions containing osteolytic activity will be dialyzed against deionized water to remove salt and lyophihzed. The fraction with the highest specific activity and the least number of protein bands on SDS-PAGE will then be further fractionated at room temperature on a second anion exchange column.
• the purity of the fractions will again be assessed visually by SDS-PAGE and 100 pg of the cleanest fraction will be dialyzed against 50 mM of Tris buffer, pH 7.6 containing 10 mM MgC12 (buffer C). This sample will be run on a 5-ml ATP-Sepharose (Sigma Immunochemicals) column. The column will be washed with 10 column volumes of butter C and bound protein eluted in 5 column volumes of a ⁇ mM ATP (Sigma Immunochemicals), also in buffer C. Protein will be located by SDS-PAGE and visualized using a silver stain kit (Sigma Immunochemicals).
• a cross tabulation method will be used to measure the relationships between osteopenia, age, gender, other contributing factors, and the presence of chaperone molecules by generating multiple-way frequency tables. For each possible combination of these variables, these tables yield a cell frequency, i.e., the number of cases in the patient population that had this particular combination.
• the cross tabulation method will allow to evaluate the reliability of the test, in other words, the statistical significance of these relationships.
• the presence of osteopenia, age, gender, other contributing factors such as medical conditions are categorical variables.
• Multiple simultaneous relations and interactions between the variables of the multipleway frequency table will be examined on the basis of log- linear equations, which allow computation of the cell frequencies that would have been expected if the variables involved were unrelated.

Applications Claiming Priority (5)

Publications (1)

Family

ID=26949659

Family Applications (1)

Country Status (5)

Families Citing this family (27)

Family Cites Families (8)

• 2002
  • 2002-01-17 JP JP2002558025A patent/JP2005503533A/ja not_active Withdrawn
  • 2002-01-17 US US10/054,171 patent/US7534419B2/en not_active Expired - Fee Related
  • 2002-01-17 EP EP02714754A patent/EP1354208A2/de not_active Ceased
  • 2002-01-17 AU AU2002247004A patent/AU2002247004A1/en not_active Abandoned
  • 2002-01-17 WO PCT/US2002/001566 patent/WO2002057795A2/en active Application Filing
• 2009
  • 2009-05-18 US US12/467,807 patent/US20090280142A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events